Clinical Trial Update: Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

View source ↗

Summary

This update describes an expanded access protocol allowing subjects previously treated with gedatolisib in the B2151009 trial to continue receiving the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gedatolisib (gedatolisib)

Snippet

Sponsor: Celcuity Inc | Conditions: Breast Neoplasm Malignant Female | Status: AVAILABLE